After the cloning of murine cytokine synthesis inhibitory factor, it was recognized that a homologous open reading frame was encoded within the Epstein-Barr virus (human herpes virus 4). This viral protein has now been termed viral interleukin 10 (vlL-10) to reflect its protein sequence homology to "cellular" Ibl0 (clbl0, either murine or human Ibl0). It is now widely accepted that vlL-10 shares many functions with clL-10, principally, the ability to enhance survival of newly infected B cells and to diminish the production of IFN-~ and II.-2 during ongoing immune reactions. The immunomodulatory effect of locally secreted vlbl0 and murine Ibl0 (mlbl0) was examined in tumor models using CL8-1 (a BL6 melanoma cell line transfected with the H-2K b class I gene) in syngeneic animals. Although parental BL6 tumor cells grow in immunocompetent syngeneic hosts, CL8-1 are rejected. To achieve local secretion of vlL-10, we generated vlbl0 retroviral vectors. While nontransduced CL8-1 cells (1 x 104) failed to grow when injected intradermally in C57BL/6 mice, CL8-1 cells (1 x 104) transduced with vlL-10 formed palpable tumors and eventually killed 80% of injected animals. Suppression of tumor rejection was also noted when CL8-1 tumors with or without vlL-10 transfection were admixed with syngeneic vlL-10-transfected fibroblasts and inoculated. Since the in vitro proliferation of the tumor was not altered after transduction with the vlL-10 gene and injection of vlD10--transduced CL8-1 does not affect the rejection of nontransduced CL8-1 inoculated at a distant site, local vlL-10 secretion appears to suppress the process of immune rejection of the target cells in a dose-dependent manner. Similar results were observed for the H-2 b MCA105 sarcoma tumor model in allogeneic BALB/c mice (H-2d). Although all animals that received nontransfected MCA105 rapidly rejected these tumors, MCA105 sarcomas transfected with vlL-10 remained palpable for up to 37 d. The local immunosuppressive effect of gene-delivered vlL-10 could be neutralized by anti-human II.-10 monoclonal antibody or could be reversed by the systemic administration of II.-2 or Ib12. In marked contrast, mlL-10 transfection of CL8-1 significantly suppressed tumor growth and frequently led to the rejection of tumor. Similar results were obtained for the murine tumor cell lines MC38 and MCA102. These results contrast the immunologic effects of vlL-10 and clL-10 and argue for divergence in the function of the vitally captured gene, which is presumably the result of altered interaction with one of the two derived II.-10 receptors. The present study, along with our recent study showing prolonged survival of cardiac allografts transduced with retroviral vlL-10, suggests that local vIL-10, but not mIL-10, secretion can suppress immune reactivity in both the syngeneic and allogeneic settings.
Th2 cells that inhibited cytokine synthesis of Thl cells (1).
The CSIF activity of IL-10 is mediated principally via its inhibitory effects on APC and accessory cell function by macrophages and dendritic ceils (2, 3) . Murine "cellular" Ibl0 (raiL-10) and human cellular 11.-10 (hlbl0) cDNA sequences exhibited a strong homology to a previously uncharacterized open reading frame in the EBu (human herpes virus 4), viral IL-10 (vlL-10), formerly termed Barn H1, C fragment rightward reading frame 1 (4, 5) . The hlLol0 and vlL-10 mature protein sequences are 84% identical, with most of their divergence found in the NH2-terminal 20 amino acids (4) . The vlbl0 gene was initially characterized as a "late" viral gene, expressed during the lyric phase of virus replication (6) , but, more recently, vlL-10 has been suggested to be an immediate early gene product (7) . The protein product of vlL-10 shares some functional properties with both hIL-10 and mIL-10 (5). vIL-10 shares many functions of cellular IL-10 (cIL-10) and mediates predominantly immunosuppressive effects through the inhibition of cytokine synthesis (II,2 and IFN-3') by human PBMC (1, 8, 9) . vIL-10 strongly reduces antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class II MHC expression (10) . However, vIL-10 does not (a) costimulate the proliferation of murine thymocytes (11) , (b) stimulate proliferation of murine mast cell lines (5, 12) , or (c) induce increased expression of class II MHC molecules on murine B cells (13) . Thus, vIL-10 appears to function as a predominantly immunosuppressive agent. These in vitro results suggest that vIL-10 could be an ideal cytokine for blunting the immune response after transplantation or potentially in the setting of autoimmune disease.
To test this hypothesis, we used a tumor system that directly reflects the in vivo immunologic environment. Some tumors in experimental animals escape T cell-mediated destruction by down-regulation of MHC class I molecule expression (14) . The importance of these molecules in tumor rejection is strongly supported by experiments in which transfection of class I MHC gene(s) leads to restoration of tumor cell immunogenicity and prevention of tumor growth in an immunocompetent host (15, 16) . Although the B16 melanoma expresses low levels of H-2 class I molecules and is poorly immunogenic (17, 18) , transfection of B16 melanoma cells with H-2K b results in increased immunogenicity and rejection (19) . We used retrovirus-mediated gene transfer to introduce the vIL-10 and mIL-10 genes into these ceils, and we studied the consequences of local cytokine production on the development of tumors in vivo. The results distinguish the effects of vIL-10 and cIL-10 in vivo and support in vitro evidence suggesting that vIL-10 is able to confer only a subset of the activities of the cIL-10. The present results, along with our recent study showing prolonged survival of cardiac allografts after retrovirus-mediated vIL-10 transduction (Qin, L., unpublished observation), indicate that local vIL-10 but not mIL-10 production can suppress immune responses in both syngeneic and allogeneic settings.
Materials and Methods
Mice. Female C57BL/6 mice and BALB/c mice, 8-12 wk old, were obtained from The Jackson Laboratory (Bar Harbor, ME). Mice were routinely screened and found to be pathogen free.
Murine Cell Lines. The CL8-1 clone was generously provided by Dr. E. Gorelik (University of Pittsburgh, Pittsburgh, PA) and used in most experiments. CL8-1 (19) was obtained after cotransfection of the BL6-8 (H-2K b-, H-2D ~ § B16 melanoma clone with a plasmid encoding the class I gene H-2K b and one encoding the bacterial neomycin phosphotransferase gene conferring sensitivity to the neomycin analogue, Geneticin (G418; GIBCO BRL, Gaithersburg, MD). MCA102 and MCA105 are methylcholanthrene (MCA)-induced murine fibrosarcomas. MC38 is a routine colon adenocarcinoma cell line. All were generously provided by Dr. S. A. Rosenberg (National Cancer Institute, National Institutes of Health, Bethesda, MD) and maintained by serial transplantation in mice (20) . Tumor cell lines were maintained as adherent cultures derived from harvesting fresh tumor specimens *10 mm in diameter. TIB81 is an H-2 b embryonic fibroblast cell line purchased from American Type Culture Collection (Rockville, MD). CL8-1, MCA102, MCA105, and MC38 ceils were maintained in RPMI 1640 (GIBCO BRL) supplemented with 10% heat-inactivated FCS, 2 mM L-glutamine, 100 IU/ml penicillin, and 100/xg/ml streptomycin. TIB81 cells were maintained in DMEM (GIBCO BRL) supplemented with 10%o FCS, 2 mM t-glutamine, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 100 U/ml penicilLin, and 100 mg/ml streptomycin.
Reagents. rhIL-2 was obtained from Dr. A. Louie (Chiron, Emeryville, CA) and had a specific activity of 18 x 106 IU/mg (21, 22) . Recombinant murine IL-12 (rmIL-12) was kindly provided by Dr. B. Hubbard (Genetics Institute, Cambridge, MA). The specific activity was 5-7 x 106 U/mg as determined in a PHA blast proliferation assay as previously described (23) . For in vivo administration, IIA2 was diluted in 0.1% mouse albumin carrier protein, mAb 19F1, which blocks both hIL-10 and vIL-10, was provided by Schering-Plough Research Institute (Kenilworth, NJ).
Construction of Vectors Carrying r i l l 0 and raiL,10.
The cDNAencoding vIL-10 and mIL-10 were subcloned into a retroviral-proviral construct termed MFG (4, 24, 25) . The cDNAs were inserted into MFG so that the translational initiation codon ATG of vIL-10 and mIL-10 protein was fused to the ATG of the retroviral env gene. We have also subdoned vIIA0 and mIL-10 cDNA into a modified MFG (termed DFG), which simultaneously expresses a neomycin transferase gene as a selectable marker (26) (Fig. 1) . The packaging cell line termed ~CRIP (27) was transfected with these proviral plasmids using the calcium phosphate method to generate stable producer cell lines. Infection and Measurement of vlIAO and mlIAO Production. Tumor or fibroblast cell lines were infected in culture using viral supernatant from the respective producer cell lines. Cells were incubated with viral supernatant containing polybrene (8/~g/ml) at 37~ for 3 h. After incubation, viral supematant was replaced with fresh medium. When the cells were infected with DFG, cells were split 48 h after the infection and selected in media containing 0.5-0.75 /~g/ml G418. Supernatant of infected cells was harvested after infection and tested for vlL-10 and mlbl0 protein using an ELISA as directed (Pharmingen, San Diego, CA). The amount of vlL-10 was determined with an ELISA, which detects both v-and hlL-10 but does not cross-react with mlL-10. Levels of mlL-10 were measured by ELISA using an mAb specific to mlL-10.
In Vivo Cell Proliferation Assay. Morphology and in vitro cell proliferation patterns were compared between vlbl0-and mlbl0-transduced and nontransduced tumors (CL8-1, MCA105, MC38). 1 x 10 s nontransduced vlbl0-transduced, and mlL-10-transduced cells were seeded into 10-cm dishes. At certain time points (1, 2, 3, 4, and 5 d after the cell split), the morphology of cells was examined, and the number of total cells in each dish was evaluated after obtaining single cell suspensions by trypsinization.
Murine Studies. The mice used in the experiments were ear tagged and randomized before inoculation with tumor. Tumor cells were inoculated intradermally in the shaved area of the left flank, and tumor establishment was determined by palpation. Tumor size was determined by measuring perpendicular tumor diameters with a vernier caliper. In some experiments, tumor cells were injected intradermally admixed with fibroblasts. All these measurements were done in a coded, blinded fashion. Systemic rhlL-2, rmlL-12, and anti-hlL-10 mAb were administered by intraperitoneal injection. Treatment groups consisted of five mice per group.
Immunohistockemistry. Tumor specimens were harvested and snap frozen 10 d after nontransfected CL8-1, CL8-1-vlL-10, or CL8-1-mlbl0 cells were inoculated into syngeneic mice. Cryostat-cut sections were fixed in cold acetone, hydrated in PBS, and incubated in protein-blocking solution (Lipshaw Immunon, Pittsburgh, PA) for 8 min. They were then incubated overnight at 4~ with rat mAbs directed against mouse CD4, CD8, and macrophages (MOMA-2; Serotec Ltd., Oxon, UK.) Isotype-matched rat IgG was used as a negative control. A biotinylated mouse primary antibody against I-A b was also used. In this case, an irrelevant biotinylated mouse mAb (anti-BRDU; Caltag Laboratories, San Francisco, CA) was used as a negative control. Positive tissue controls consisted of frozen sections of spleens from B10 and BALB/c mice. After buffer washes, endogenous peroxidase activity was quenched with 0.6% H202 in methanol. Species-absorbed biotinylated mouse anti-rat F(ab')2 (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) was applied to sections incubated with unlabeled primary antibodies, followed by streptavidin peroxidase (Boehringer Mannheim, Indianapolis, IN) and 3'-amino-9-ethylcarbazole (Biomeda Corp., Foster City, CA). In the case of anti-I-A b and its negative control, the biotinylated secondary antibody was eliminated. Sections were counterstained with hematoxylin and mounted in Crystal Mount (Biomeda Corp.).
Statistical Analysis. The percentage of mice with tumor and tumor size in each group were calculated and compared with other groups using a standard Student's t test. The differences were considered statistically significant when the P value was <0.05.
Results
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v-and mlL-10 secreted from target cells infected with retrovirus are shown in Table 1 . These levels from infected cells were higher than those from COS-7 ceils transfected with an expression plasmid (pJJRU3-vIbl0), which has a modified SV40 promoter (28) (19, 29) . Titered doses of CL8-1 cells and BL6 cells were inoculated intradermally into syngeneic mice to confirm this difference (C57BL/6, groups of five mice; data not shown). Parental BL6 cells grew as intradermal tumors in all mice, even when as few as 1 x 104 cells were inoculated. At the same cell dose, CL8-1 was poorly tumorigenic, inducing tumors in no more than 0-20% of mice. Only when >1 x 105 CL8-1 cells were inoculated intradermally into syngeneic mice did 60-80% of the animals develop a palpable tumor. Expression of the class I gene (H-2K b) in tumor cells is associated with a reduced tumorigenic potential in syngeneic recipients. In an allogeneic setting (H-2 d, BALB/c; data not shown), all tumors were rejected within 2-3 wk after inoculation.
To examine the mechanism of rejection of the CL8-1 cells in syngeneic animals, varying doses of CL8-1 cells were inoculated intradermally into irradiated (a sublethal dose of 500 g to whole body) or nonirradiated C57BL/6 mice ( 
rill0 Gene Transduction Can Suppress Immune Rejection of Tumor Cells In Vim A series of experiments was performed
to determine if local rib10 secretion could suppress immunemediated rejection of CL8-1 tumor cells inoculated intradermally into syngeneic animals. 104 CL8-1 cells, transduced with MFG-vlL-10 (CL8-1-vlL-10, 72.56 ng/106 cells per 48 h), were injected intradermally into syngeneic C57BL/6 animals. Although nontransduced CL8-1 cells failed to grow in any of these animals, CL8-1-vIL-10 displayed palpable tumors in 80% of injected animals. All of these animals developed progressively growing tumors (Fig. 3, B and E) . The size of the CL8-1-vIbl0 tumors at day 35 (89.6 _+ 67.7 mm 2) was significantly larger than that of nontransfected CL8-1 tumors (0 +-0 mm 2, P = 0.018). All of the animals inoc- To determine if transduced fibroblasts could also be used to deliver vlL-10 at the site of tumor cells, CL8-1 or CL8-1-vlL-10 was admixed with TIB81 fibroblasts, which were transduced with both vlL-10 and Neo (TIB81-vlL-10) or Neo only (TIB81-Neo; Similar results were also observed in an allogeneic setting in which tumor is normally rejected rapidly. MCA105 (H-2b), transduced with DFG-vlLq0 and selected for Neo resistance (MCA105-vlL-10, 83.42 ng/106 cells per 48 h), were injected into allogeneic animals (BALB/c, H-2a). Although all of the animals that received nontransfected MCA105 rejected the tumor by 14 d after injection, MCA105-vlL-10 remained palpable for up to 37 d (Fig. 4, A and B) . While all of the vlL-10-transfected tumors were eventually rejected, this process was significantly delayed (mean _+ SD = 23.2 + 11.7 d) when compared with nontransduced MCA105 tumors (6.4 + 6.2 d, P = 0.022). These results indicate that local vlbl0 secretion can suppress immune rejection of both syngeneic and allogeneic tumors.
To examine the in vivo expression of the transduced vlL-10 gene in progressively growing tumors, CLf-I-vlL10 cells were inoculated intradermally, harvested from resultant tumors (1.0 cm diameter) 4 wk after the inoculation, and cultured in vitro (Re-CL8-1-vlL-10). The secretion of vlbl0 in culture supernatant was examined by ELISA. R.e-CL8-1-vlL-10 cells expressed vlbl0 protein at the level of 25.4 ng/10 6 cells per 48 h for up to 4 wk after harvest (Table 1) . Class I expression of Re-CL8-1-vlL-10 was also examined using anti-H-2K b and flow cytometry. The level of the class I expression was not altered (data not shown). Although we did not evaluate the expression of IL-10 in rejecting tumors, which is operationally difficult to perform in tumors that are only barely palpable during the first 10 d after inoculation, we have shown that ILl0 effects are abrogated by irradiation (data not shown) and that the rib10, mlL-10, and wild-type animal tumors had very different immunohistochemical patterns at 10 d (see below). Although technically possible, the use of in situ hybridization techniques, RT-PCR, and immunohistochemistry to detect mlL-10 (or vlL-10) protein or messenger RNA in vivo would only allow demonstration of gross differences, and these methods were considered to be far less sensitive than the ELISA performed in vitro before inoculation.
The Local Secretion of vlLlO Does Not Affect Rejection of a Nontransduced Tumor at a Distant Site.
To examine whether locally secreted vlL-10 protein also has systemic effects, 1 x 104 nontransduced CL8-1 cells were injected in the right flank of C57BL/6, and 1 x 104 CLf-I-vlI~10 (42.3 ng/106 cells per 48 h, group 1) or nontransduced CLf-1 cells (group 2) were injected in the left flank concurrently (Fig. 5, A and  D) . All animals in group 2 rejected the tumor in both sides. 
The Immunosuppressive Effects of vlL10 Can Be Reversed by the Administration of Anti-vlLlO Antibody or by Addition of the Cytokines 11.,2 or 11,I2
. Anti-hlL-10 antibody (0.5 mg per mouse) was administered as intraperitoneal injections (1.0 ml) 24 h before tumor inoculation and on day 6 after inoculation. C57BL/6 mice were inoculated with 5 x 104 CL8-1-vlL-10 (81.1 ng/106 cells per 48 h) or nontransduced CL8-1 cells on day 0 (Fig. 5, B and E) . While 80% of animals inoculated with CL8-1-vlD10 developed progressively growing tumors, CL8-1-vlbl0 cells failed to grow in animals receiving anti-hlL-10 antibody. The size of the CLS-I-vlL-10 tumors at day 28 (18.0 + 10.4 mm 2) was significantly larger than that of CLS-I-vlL-10 with anti-vlL-10 antibody (0 -+ 0 mm 2, P = 0.005). Significant neutralization of the vlL-10 effect was demonstrated with administration of anti-vlL-10 antibody. The growth of nontransduced CL8-1 tumor was not altered upon administration of anti-vlL-10 antibody. To examine whether other cytokines could reverse the vlL-10 effects, rhlL-2 (600,000 IU daily from day 7 to day 13) or rmlL-12 (0.1/zg daily from day 7 to day 13) was administered systemically (intraperitoneally) into C57BL/6 mice that received intradermal injection of 5 x 104 CL8-1-vlL-10 (67.3 ng/106 cells per 48 h) or nontransduced CL8-1 cells on day 0 (Fig. 5, C and F) . All mice that received CL8-1-vlD10 cells developed palpable tumor within 10 d, while nontransduced CL8-1 tumors progressed in only 40-60% of mice. In this experiment, the growth of CL8-1-vlL-10 tumors as well as of nontransduced CL8-1 tumors was significantly inhibited after systemic IL-2 or IL-12 administration. In the rhlL-2-administered animals, the percentage of animals with palpable tumor (20%) and the tumor area (0.8 _+ 1.8 mm 2, P <0.0001) at day 35 were similar to those in the group administered rmlL-12 (0%, 0 -+ 0 mm 2, P <0.0001), when compared with that of control or Hanks' solution-administered groups (38.2 +-7.4 mm 2 or 37.6 + 3.2 ram2). Thus, systemic IL-12 or IL-2 administration significantly reversed vlL-10-mediated suppression of tumor rejection.
Profound Differences Exist between vlL10 and mlblO in Immunomodulatory Functions.
To analyze the differences between vlL-10 and raiL-10 in immunomodulatory functions, varying doses of nontransduced CL8-1, CL8-1-vlL-10 (56.5 ng/106 cells per 48 h) and CL8-1-mlL-10 (51.0 rig/10 + cells per 48 h) cells were injected into C57BL/6 mice (Fig. 6, A and B) . When 1 x 104 cells were injected into the animals, 60% of the animals with CLS-I-vlL-10 displayed palpable growing tumors, while tumor was identified in none of the animals receiving nontransduced CL8-1 or CL8-1-mlbl0. For the size of the tumors at day 23, values were 7.2 _+ 6.6 mm 2 in CL8-1-vlL-10 tumors and 0 -+ 0 mm 2 in both CL8-1-mlL-10 and nontransduced CL8-1 tumors, a statistically significant difference (P = 0.04). When 10 s cells were injected into animals, 100% or 60% of the animals with CLS-I-vlL10 cells or nontransduced CL8-1 cells developed palpable progressively growing tumors, respectively. All animals receiving 
Immunohistological Evaluation of CLS-1, CL8-1-vlL, IO, and CL8-1-mlblO Tumors.
After staining of nontransduced CL8-1, CL8-1-vlL-10, and CL8-1-mlL-10 tumors with mAbs to T cell subsets, a specific cellular CD4 + and CD8 + T cell infiltrate was identified. Nontransduced CL8-1 tumors were infiltrated with a large number of CD4 § and a moderate number of CD8 + lymphocytes (Fig. 7, A -C ) . Conversely, only a few CD4 + and CD8 + lymphocytes were observed within CL8-1-vlL-10 tumors (Fig. 7, G-I ). CL8-1-mlL-10 tumors displayed a modest number of both CD4 + and CD8 + lymphocytes (Fig. 7, D-F) . Interestingly, CD4 § and CD8 + lymphocytic infiltration of CL8-1-vlL-10 tumor differs from the characteristic dense infiltration of CD4 + and CD8 § lymphocytes surrounding regressing nontransduced CL8-1 or CL8-1-mlL-10. Additionally, CD8 + lymphocytes were observed primarily in the peritumoral area of CL8-1-mlL-10 tumors and within the nontransduced CL8-1 tumors.
Discussion
We have constructed retroviral vectors that allow for high level secretion of vlL-10 and mlL-10 by transduced cells. Using this vector system, we demonstrated that local vlL-10 secretion can inhibit or suppress immune rejection of immunogenic tumor cells in both syngeneic and allogeneic settings. The local secretion of vlL-10 does not affect the rejection of a nontransduced tumor at a distant site. These results suggest that the local secretion of vlL-10 protein does not have systemic effects but, rather, only local immunosuppressive effects. We have also shown that vlL-10-transduced nontransformed fibroblasts, when admixed with tumor cells, yield similar immunosuppressive effects in vivo. Furthermore, when vlL10-secreting fibroblasts are combined with vlL-10-secreting tumor cells and inoculated in vivo, the extent of the immunosuppression is greater than that observed with vIL-10-secreting tumor cells alone. Thus, the immunosuppressire effects associated with vIL-10 are dose dependent, but independent of the source of the vIL-10.
These vIL-10 effects were abrogated when anti-vlL-10 antibody or immunostimulatory cytokines, such as IL-2 and IL-12, were administered systemically to the tumor-bearing animals in vivo. This result suggests that vIL-10 protein secreted by the tumor cells is responsible for this observation and that the mechanism of the vIL-10 immunosuppression might in-volve suppression of cytokine synthesis. IL-12 induces T and NK cells to produce IFN-3' at high levels (30) and enhances primarily a Thl cellular immune response (31) . IL-2 is a growth factor that stimulates the proliferation of cytotoxic T cells, Th, and NK cells, and generates LAK activity (32) (33) (34) (35) . Thus, immunosuppressive effects of vlL-10 might be mediated by inhibition of IL-12-associated functions, including IFN-3~ induction, NK or Thl function and/or differentiation, and IL-2 synthesis by cytotoxic T cells. This interpretation is compatible with the previous findings observed with clL-10 in vitro. (1, 8, 9, 36-38) .
The effects of vlL-10 we have observed in vivo support the idea that vlLol0 has retained the CSIF or macrophage/dendritic cell-deactivating activities of clL-10. It has been suggested that the gene transfer of vlL-10 using our retroviral vectors prolonged cardiac allograft survival in a heterotopic, nonvascularized allograft model, and it has been demonstrated that, when allografts were transduced with vlL-10, decreased numbers of CD2 +-, CD3 +-, CD4 +-, and CD8+-expressing lymphocytes were observed (Qin, L., unpublished observation). Our immunohistochemical results also showed that infiltration by CD4 + and CD8 + lymphocytes in animals bearing CL8-1-vlL-10 tumors was markedly reduced compared with that in nontransduced CL8-1 or CLS-I-mlL-10 tumors. These observations are consistent with the notion that h-and vlL-10 block the Ag-specific proliferation of both total T cells and CD4 + Thl-or Th2-1ike T cell clones (10) . However, the in vivo effect of mlL-10 expression by the same tumor cells was, surprisingly, to stimulate rejection of the tumor. clL-10 has additional activities, such as costimulation of T cell/thymocyte growth and differentiation (11, 39, 40) , chemotactic effects on CD8 cells (41) , and induction of adhesion molecule expression by endothelial cells (42) , which vlL-10 may lack (11, 39) .
Recent studies by others (42, 43) also suggest that clbl0 may have complex effects in vivo. The expression of clL-10 under control of the insulin promoter in transgenic mice is associated with pronounced pancreatic inflammation, dominated by the presence of CD4 + and CD8 + T cells and B lymphocytes. The exocrine tissue is completely destroyed, but the islets of Langerhans are intact and appear to function normally (42) . In nonobese diabetic mice, production of IL-10 by islet cells markedly accelerated immune-mediated destruction of 3 cells (43) . In contrast, systemic administration of clL-10 blocked the onset of diabetes in nonobese diabetic mice (44) . Thus, our results, along with those of Wogensen and co-workers, suggest that stimulatory effects of clL-t0 on T cells and other cells may obscure the consequences of its "suppressive" effects on the APC and accessory cell functions of macrophages and dendritic cells when clL-10 is expressed locally at high levels. Our studies with systemic administration of hlL-10 (Berman, R., T. Suzuki, H. Tahara, S. K. Narula, P. D. Robbins, and M. T. Lotze, manuscript submitted for publication) suggest that it has significant immunostimulatory functions, promoting the rejection of established day 7 murine tumors when high doses (higher than 20 #g per mouse) are administered daily for 7 d.
The basis for the apparent differences in clL-10 and vlL-10 activities is only partially understood, cDNA clones encoding mouse and hlL-10R ligand-binding chains have been isolated and characterized (45, 46) . Both rlL-10R bind their respective clbl0 ligand with high affinity yet exhibit at least a 100-fold lower affinity for vlL-10 than for clL-I0 (46a). Nevertheless, vlL-10 stimulates proliferation of mlL-10R-transduced Ba/F3 cells with a specific activity only 3-10-fold lower than clL-10, as is observed on normal cells that respond to both clbl0 and vlL-10 (46a). These and other observations (Moore, K. W., unpublished observations) support the notion that IL-10R expression on vlL-10-responsive cells is composed of the ligand-binding (c~) chain that binds, and one or more additional components that are required for interaction with vlL-10. Further studies of IL-10R structure should clarify the nature of the vlL-10 "defect:' The immunosuppressive effects of locally expressed vlL-10 suggest the possible application of vlL-10 in allogeneic organ transplantation. Although organ transplantation is now recognized as an established life-saving measure for various diseases (47), most patients who receive organ or cellular transplantation require systemic immunosuppression for the rest of their lives using cyclosporin A or FKS06 (48) . During the prolonged period of general immunosuppression, patients are susceptible to opportunistic infections and malignancies. In theory, if local immunosuppression similar to that observed in this study could be achieved at the site of the transplanted organ by gene transfer, immune rejection of the graft could be blocked without disturbing systemic immune function.
In contrast to vlL-10, our results with clL-10 suggest that it could be developed as an antitumor reagent when used in a gene therapy strategy. The possibility of using clL-10 as an antitumor agent in gene therapy has been reported by Richter et al. (49) using mlbl0-transduced Chinese hamster ovary (CHO) cells. CHO-IL-10 cells grew normally in vitro but did not grow as tumors in immunodeficient animals (either nude or SCID mice). This effect was IL-10 dose-dependent, and CHO-IL-10 cells also suppressed the growth of tumors if coinjected with nontransduced CHO cells. Immunohistologic examination suggested that raiL-10 inhibited the infiltration of macrophages that was observed for tumors containing nontransduced CHO cells. Although direct interpretations of these results are limited because of the nature of the tumor selected and the use of immunodeficient animals, they suggest that, under certain circumstances, clL-10 can stimulate an immune response (Velu, T., and G. Forni, personal communication). Consistent with these results, we have shown that establishment of CL8-1 melanoma cells (Fig.  6 ), MC38 colon cancer cells, and MCA102 fibrosarcoma cells can be abrogated in syngeneic, immunocompetent mice (C57BL/6) (data not shown). We have also shown that the abrogation of tumor establishment leads to the promotion of protective immunity to a subsequent challenge with nontransduced tumor cells. Therapeutic effects are now being tested to examine the potential clinical application of this strategy. The discordant in vivo effects observed when comparing vlL-10 and mlL-10 should be noted for further characterization of these cytokines with multiple functions.
